Abstract
Emicizumab is a bi-specific humanized monoclonal antibody mimicking the factor (F) VIII cofactor activity in mediating the activation of FX by FIXa. Recent observations showed that emicizumab when added to pooled normal plasma (PNP), hemophilic plasma or PNP added with unfractionated heparin is able to interfere with coagulation assays. To further explore the mechanisms of assay interference we investigated the effect of emicizumab on global coagulation assays for the PNP added with two direct oral anticoagulants, apixaban or argatroban. Aliquots of PNP were added with purified apixaban or argatroban at a concentration of 500 ng/mL and emicizumab at concentrations ranging from 0 to 100 µg/mL. Plasma samples were then tested for the activated partial thromboplastin time (APTT) and for thrombin generation (the latter for the apixaban plasma only). Emicizumab at a 25–50 µg/mL shortened the APTT of the PNP with or without apixaban or argatroban. The extent of correction was greater for the apixaban or argatroban plasma and amounted to 35% or 42%, respectively. The parameters of thrombin generation (lag-time and time-to-peak) for the PNP supplemented with apixaban were shortened by 30% or 25%, respectively and the endogenous thrombin potential and the peak-thrombin were marginally affected. Emicizumab attenuates in vitro the anticoagulant activity of the PNP induced by apixaban or argatroban as documented by the correction of prolonged APTT and velocity of thrombin generation (i.e., lag-time and time-to-peak). Whether the above effects have any relevance in vivo is unknown.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Uchida N, Sambe T, Yoneyama K, Fukazawa N, Kawanishi T, Kobayashi S et al (2016) A first-in-human phase 1 study of ACE910, a novel factor VIII-mimetic bispecific antibody, in healthy subjects. Blood 127:1633–1641
Oldenburg J, Mahlangu JN, Kim B, Schmitt C, Callaghan MU, Young G et al (2017) Emicizumab prophylaxis in hemophilia A with inhibitors. N Engl J Med 377:809–818
Mahlangu J, Oldenburg J, Paz-Priel I, Negrier C, Niggli M, Mancuso ME et al (2018) Emicizumab prophylaxis in patients who have hemophilia A without inhibitors. N Engl J Med 379:811–822
Adamkewicz JI, Chen DC, Paz-Priel I (2019) Effects and interferences of emicizumab, a humanised bispecific antibody mimicking activated factor VIII cofactor function, on coagulation assays. Thromb Haemost 119:1084–1093
Chantarangkul V, Clerici M, Bressi C, Giesen PL, Tripodi A (2003) Thrombin generation assessed as endogenous thrombin potential in patients with hyper- or hypo-coagulability. Haematologica 88:547–554
Hemker HC, Giesen P, Al Dieri R, Regnault V, de Smedt E, Wagenvoord R et al (2003) Calibrated automated thrombin generation measurement in clotting plasma. Pathophysiol Haemost Thromb 33:4–15
Francis JL, Hursting MJ (2005) Effect of argatroban on the activated partial thromboplastin time: a comparison of 21 commercial reagents. Blood Coagul Fibrinolysis 16:251–257
Lenting PJ, Donath MJ, van Mourik JA, Mertens K (1994) Identification of a binding site for blood coagulation factor IXa on the light chain of human factor VIII. J Biol Chem 269:7150–7155
Takeyama M, Wakabayashi H, Fay PJ (2012) Factor VIII light chain contains a binding site for factor X that contributes to the catalytic efficiency of factor Xase. Biochemistry 51:820–828
Kitazawa T, Esaki K, Tachibana T, Ishii S, Soeda T, Muto A et al (2017) Factor VIII-mimetic cofactor activity of a bispecific antibody to factors IX/IXa and X/Xa, emicizumab, depends on its ability to bridge the antigens. Thromb Haemost 117:1348–1357
Minami H, Nogami K, Yada K, Ogiwara K, Furukawa S, Soeda T et al (2019) Emicizumab, the bispecific antibody to factors IX/IXa and X/Xa, potentiates coagulation function in factor XI-deficient plasma in vitro. J Thromb Haemost 17:126–137
Makris M, Iorio A, Lenting PJ (2019) Emicizumab and thrombosis: the story so far. J Thromb Haemost 17:1269–1272
Author information
Authors and Affiliations
Contributions
AT conceived the study. VC supervised preparation of test plasmas and laboratory testing. AT wrote the manuscript. MC, LP and ES, tested samples. FP and all the other authors reviewed data and revised the manuscript.
Corresponding author
Ethics declarations
Conflict of interest
The authors declare that they have no conflict of interest.
Additional information
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
About this article
Cite this article
Tripodi, A., Chantarangkul, V., Padovan, L. et al. Effect of emicizumab on global coagulation assays for plasma supplemented with apixaban or argatroban. J Thromb Thrombolysis 49, 413–419 (2020). https://doi.org/10.1007/s11239-019-01993-9
Published:
Issue Date:
DOI: https://doi.org/10.1007/s11239-019-01993-9